Rapt Therapeutics (NASDAQ:RAPT) Downgraded by Clear Str to “Hold”

Clear Str cut shares of Rapt Therapeutics (NASDAQ:RAPT) from a strong-buy rating to a hold rating in a research note issued to investors on Tuesday,Zacks.com reports.

Other equities analysts also recently issued research reports about the stock. JPMorgan Chase & Co. lifted their price target on shares of Rapt Therapeutics from $55.00 to $57.00 and gave the company an “overweight” rating in a report on Wednesday, November 12th. TD Cowen restated a “hold” rating on shares of Rapt Therapeutics in a research note on Tuesday. Leerink Partnrs upgraded Rapt Therapeutics from a “hold” rating to a “strong-buy” rating in a research note on Thursday, September 25th. HC Wainwright downgraded Rapt Therapeutics from a “buy” rating to a “neutral” rating and set a $58.00 price objective on the stock. in a research report on Tuesday. Finally, Piper Sandler cut Rapt Therapeutics from an “overweight” rating to a “neutral” rating and set a $58.00 target price for the company. in a research report on Tuesday. One research analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating, ten have assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock has a consensus rating of “Hold” and an average price target of $48.22.

Rapt Therapeutics Stock Up 64.0%

Shares of RAPT opened at $57.57 on Tuesday. The business has a 50-day simple moving average of $33.31 and a two-hundred day simple moving average of $23.72. Rapt Therapeutics has a 52 week low of $5.67 and a 52 week high of $57.61. The stock has a market cap of $1.60 billion, a price-to-earnings ratio of -5.21 and a beta of 0.45.

Rapt Therapeutics (NASDAQ:RAPT) last announced its quarterly earnings data on Thursday, November 6th. The company reported ($0.65) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.88) by $0.23. On average, equities analysts anticipate that Rapt Therapeutics will post -2.14 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Rapt Therapeutics

A number of institutional investors and hedge funds have recently made changes to their positions in the business. Invesco Ltd. increased its holdings in shares of Rapt Therapeutics by 411.7% in the 1st quarter. Invesco Ltd. now owns 58,901 shares of the company’s stock worth $72,000 after buying an additional 47,391 shares during the last quarter. AQR Capital Management LLC purchased a new position in Rapt Therapeutics in the first quarter worth about $188,000. Dimensional Fund Advisors LP bought a new stake in Rapt Therapeutics during the third quarter worth approximately $231,000. Bridgeway Capital Management LLC increased its stake in Rapt Therapeutics by 32.0% during the third quarter. Bridgeway Capital Management LLC now owns 20,625 shares of the company’s stock worth $532,000 after acquiring an additional 5,000 shares during the last quarter. Finally, UBS Group AG raised its position in Rapt Therapeutics by 680.3% during the third quarter. UBS Group AG now owns 28,808 shares of the company’s stock valued at $743,000 after purchasing an additional 25,116 shares during the period. 99.09% of the stock is owned by hedge funds and other institutional investors.

Trending Headlines about Rapt Therapeutics

Here are the key news stories impacting Rapt Therapeutics this week:

• Positive Sentiment: GSK agreed to acquire Rapt in a definitive deal valuing the company at about $2.2 billion (~$58.00 per share), providing a cash exit at a sizable premium to recent trading and directly causing the stock’s sharp rise. Article Title
• Positive Sentiment: Multiple outlets highlight that GSK gains a late‑stage food allergy antibody (ozureprubart) from Rapt’s pipeline — a strategic fit that supports the acquisition rationale and the deal premium. Article Title
• Positive Sentiment: Rapt’s investors and prior backers benefit: Forbion confirms this is a successful exit from its Growth Fund III, which validates the deal’s value to venture/early investors. Article Title
• Neutral Sentiment: Analysts have mostly left ratings and price targets around the announced deal price (Wells Fargo equal weight with $58 PT; Lifesci/TD Cowen hold), which implies limited near‑term upside beyond the acquisition consideration. Article Title
• Negative Sentiment: Several law firms have announced investigations or shareholder class‑action interest probing whether Rapt’s board negotiated a fair price, which could lead to litigation, procedural delays or settlement costs ahead of closing. Investors should monitor any formal complaints. Article Title
• Neutral Sentiment: Coverage pieces and buy/analysis notes (e.g., Seeking Alpha, The Motley Fool) frame Rapt as an attractive biotech target highlighting its long‑acting IgE candidate; useful context for strategic rationale but secondary to the binding deal terms. Article Title

Rapt Therapeutics Company Profile

RAPT Therapeutics, Inc (NASDAQ:RAPT) is a clinical-stage biotechnology company developing novel therapeutics for autoimmune and allergic diseases. Founded in 2013 and headquartered in San Diego, California, RAPT applies tissue-selective immunology to design small molecule and biologic candidates that modulate immune cell trafficking and tissue-resident pathways. The company’s research platform enables the identification of targets that drive tissue inflammation with the goal of achieving improved efficacy and safety profiles over current therapies.

The company’s lead asset, RPT193, is an orally available antagonist of the CC chemokine receptor 4 (CCR4), currently in clinical development for atopic dermatitis and allergic asthma.